肌萎缩侧索硬化症 (ALS) 治疗市场 - 全球产业规模、份额、趋势、机会、预测：按疗法、类型、分销管道、地区和竞争格局划分，2021-2031 年

全球肌萎缩侧索硬化症 (ALS) 治疗市场预计将从 2025 年的 6.9203 亿美元增长到 2031 年的 9.7667 亿美元，复合年增长率为 5.91%。

该市场涵盖多种药物干预措施和缓解疾病，旨在控制症状、延缓神经退化并延长患有这种进行性运动神经元疾病的患者的生存期。推动这一增长的关键因素包括全球肌萎缩侧索硬化症 (ALS) 发病率的上升和人口老化，这两方面都增加了对有效神经系统护理的需求。此外，对基因研究和开发以及新型生物标记发现的大量投资正在推进临床开发平臺，为超越暂时性市场波动的长期产业扩张奠定了坚实的基础。

据「我是渐冻人症」（I AM ALS）组织称，2024年，该组织的联合倡导工作成功争取到2.58亿美元的联邦资金，用于支持渐冻人症的研究和扩大治疗范围的项目。儘管有如此强大的资金支持，市场仍面临许多挑战，因为新治疗方法往往价格高昂，导致报销门槛高，患者难以获得治疗。这种经济障碍，加上后期临床试验候选药物的高退出率，为新参与企业创造了复杂的商业环境。

市场驱动因素

来自病患权益倡导团体和非营利基金的大力支持是市场发展的关键催化剂，能够显着降低早期研发风险，并促进更稳健的研发生态系统的形成。这些组织透过投入大量资金用于探索性生物学和生物标记开发，填补了神经退化性疾病候选药物经常面临的资金缺口。正如Target ALS在其2024年年度报告中所述，该组织成功完成了一项2.5亿美元的资金筹措宣传活动，旨在推动创新科学并加速药物研发的里程碑。这笔未经稀释的资金注入使生物製药公司能够追求高风险、高回报的目标（否则这些目标可能会被忽视），并确保源源不断的潜在疗法进入临床研发管线。

随着新製剂和基因药物成功渗透市场，疾病修正治疗疗法和症状管理疗法的日益普及，同时也拓宽了商业性前景。治疗方法的增加，患者对现有治疗方法的持续接受，支撑了产业收入，并凸显了ALS治疗的经济可行性。例如，三菱田边製药于2024年11月宣布，该公司2024财年上半年销售额达2,326亿日元，较去年同期成长6.0%。这一成长动能主要归功于其ALS治疗药物Radica ORS在北美市场的强劲表现。此外，渤健公司于2024年10月报告称，其罕见疾病业务板块（包括ALS治疗药物Calsodi）第三季度销售额达4.95亿美元，凸显了针对神经系统疾病的治疗方法的巨大市场价值。

市场挑战

新治疗方法的高昂成本和严格的报销标准对肌萎缩侧索硬化症 (ALS) 治疗药物的全球市场商业性扩张构成了重大障碍。儘管临床开发平臺活跃，但新兴药物的市场潜力往往受限于资金取得。当保险公司和医疗保健机构因药品价格高而实施限制性报销政策时，患者的用药途径就会受到限制，製药公司的收入规模也会缩水。这种资金摩擦不仅限制了已通过核准产品的即时市场渗透，也意味着未来相关人员的投资回报波动，并可能减缓产业可持续成长所需的长期资本流入。

近期数据显示，患者群体面临巨大的经济压力，凸显了这个经济困境。美国肌萎缩侧索硬化症协会引用的一项2025年研究估计，确诊肌萎缩侧索硬化症后，联邦医疗保险受益人在一年内将花费超过47,000美元，是普通受益人平均支出的三倍多。如此高昂的支出迫使支付方实施严格的报销标准，延长药物市场渗透时间，并使新药进入市场的商业性环境更加复杂。

市场趋势

反义寡核苷酸（ASO）疗法的兴起代表着市场格局的重大转变，它将治疗模式从一般的症状治疗转向针对特定基因突变（例如FUS和SOD1）的精准医疗。这一趋势的特点是许可活动日益活跃，以及旨在拓展抑制毒性蛋白产生的基因疗法产品线的高价值商业合作。例如，2024年11月，大冢製药株式会社宣布已从​​Ionis公司获得urefnersen的全球独家生产和销售权，urefnersen是一种正在研发用于治疗FUS相关ALS的ASO。该协议包括1000万美元的首付款。这项策略承诺凸显了业界对基因静默机製作为未来治疗性介入关键手段的日益认可。

同时，针对神经发炎和氧化压力通路的研究正得到策略性加强，旨在解决驱动疾病进展（超出运动神经元保护范围）的系统性免疫失调问题。生物製药公司正日益重视免疫调节候选药物，例如调节性T细胞（Treg）增强疗法，以减轻与神经退化相关的发炎级联反应。在2024年10月的新闻稿中，Coya Therapeutics成功完成了约1000万美元的私募融资，用于资助其旗舰生物候选药物COYA 302的临床和临床前开发，该药物靶向这些特异性的抗炎通路。持续涌入以免疫系统为中心的研发管线的资金，凸显了该产业正转向采用多机制方法来阻止功能衰退。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗类型划分（药物治疗[Riluzole、Edaravone奉等]、干细胞治疗等）
  • 类型（散发性 ALS、遗传性ALS）
  • 分销管道（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美肌萎缩侧索硬化症（ALS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球肌萎缩侧索硬化症（ALS）治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Biogen
• Mitsubishi Tanabe Pharma
• Sanofi
• Roche
• Amylyx Pharmaceuticals
• Ionis Pharmaceuticals
• Wave Life Sciences
• Orphazyme
• Cleveland Clinic Spinouts
• Lundbeck

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market is projected to expand from USD 692.03 Million in 2025 to USD 976.67 Million by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.91%. This market includes a variety of pharmaceutical interventions and disease-modifying agents aiming to manage symptoms, slow neurodegeneration, and extend survival for patients with this progressive motor neuron disease. Key drivers of this growth include the rising global incidence of ALS and an aging population, both of which increase the need for effective neurological care. Additionally, significant investment in genetic research and the discovery of novel biomarkers are advancing the clinical development pipeline, establishing a strong foundation for long-term industry expansion beyond temporary market fluctuations.

According to the I AM ALS organization, collaborative advocacy efforts in 2024 successfully secured $258 million in federal funding to bolster ALS research and expanded access programs. Despite this strong financial support, the market faces considerable challenges due to the high costs of novel therapies, which often encounter strict reimbursement barriers that limit patient accessibility. This economic hurdle, coupled with high attrition rates for drug candidates in late-stage clinical trials, continues to complicate the commercial environment for new market entrants.

Market Driver

Robust support from patient advocacy groups and non-profit funding acts as a vital catalyst for the market, significantly de-risking early-stage research and cultivating a stronger development ecosystem. By directing major capital into discovery biology and biomarker development, these organizations bridge the financial gaps frequently encountered by neurodegenerative therapeutic candidates. As noted in their 2024 Annual Report, Target ALS successfully completed a $250 million capital campaign specifically aimed at fueling innovative science and accelerating drug discovery milestones. This injection of non-dilutive funding enables biopharmaceutical companies to pursue high-risk, high-reward targets that might otherwise be neglected, ensuring a steady flow of potential treatments entering the clinical pipeline.

The rising adoption of disease-modifying and symptom-management therapies is simultaneously broadening the commercial landscape, fueled by the successful market penetration of new formulations and genetic medicines. As therapeutic availability increases, patient uptake of established treatments continues to support industry revenues, confirming the economic viability of ALS therapeutics. For instance, according to Mitsubishi Tanabe Pharma in November 2024, the company achieved a 6.0% year-on-year revenue increase to 232.6 billion yen for the six months ended September 2024, a growth trajectory attributed to the strong performance of its ALS treatment, Radicava ORS, in North America. Additionally, Biogen reported in October 2024 that its rare disease franchise, which includes the ALS therapy Qalsody, generated $495 million in third-quarter revenue, highlighting the substantial market value of targeted neurological interventions.

Market Challenge

The exorbitant cost of novel therapies and the associated strict reimbursement hurdles create a significant barrier to the commercial expansion of the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market. Although the clinical pipeline is active, the market potential for emerging drugs is often limited by economic inaccessibility. When insurers and healthcare systems enforce restrictive coverage policies due to high drug pricing, patient access is constrained, which directly reduces revenue volume for pharmaceutical developers. This financial friction not only limits the immediate market uptake of approved products but also implies a precarious return on investment for future stakeholders, potentially slowing the long-term capital flow needed for sustained industry growth.

This economic difficulty is highlighted by recent data demonstrating the severe financial pressure on the patient population. According to a 2025 study cited by the ALS Association, medical expenses for Medicare beneficiaries in the first year following an ALS diagnosis exceeded $47,000, a figure more than three times higher than that of the average beneficiary. Such high expenditure levels force payers to implement rigorous reimbursement criteria, thereby extending the timeline for market penetration and complicating the commercial landscape for new therapeutic entrants.

Market Trends

The rise of Antisense Oligonucleotide (ASO) therapies marks a critical shift in the market, moving the treatment paradigm from general symptomatic management to precision medicine targeting specific genetic mutations such as FUS and SOD1. This trend is defined by increased licensing activity and high-value commercial partnerships aimed at expanding the pipeline of genetic medicines capable of silencing toxic protein production. For example, Otsuka Pharmaceutical Co., Ltd. announced in November 2024 that it secured exclusive global rights from Ionis to manufacture and market the investigational ASO ulefnersen for FUS-associated ALS, a deal structured with an upfront payment of $10 million. This strategic commitment confirms the growing industrial valuation of gene-silencing mechanisms as a primary modality for future therapeutic interventions.

Simultaneously, there is a strategic intensification of research focusing on neuroinflammation and oxidative stress pathways, looking beyond motor neuron protection to address the systemic immune dysregulation that drives disease progression. Biopharmaceutical developers are increasingly prioritizing immunomodulatory candidates, such as Regulatory T cell (Treg) enhancing therapies, to mitigate the inflammatory cascade associated with neuronal degeneration. According to a press release from Coya Therapeutics in October 2024, the biotechnology firm successfully closed a private placement of approximately $10 million specifically to fund the clinical and preclinical advancement of its lead biologic candidate, COYA 302, which targets these specific anti-inflammatory pathways. This continued capital inflow into immune-centric pipelines highlights the sector's pivot toward multi-mechanistic approaches intended to halt functional decline.

Key Market Players

• Biogen
• Mitsubishi Tanabe Pharma
• Sanofi
• Roche
• Amylyx Pharmaceuticals
• Ionis Pharmaceuticals
• Wave Life Sciences
• Orphazyme
• Cleveland Clinic Spinouts
• Lundbeck

Report Scope

In this report, the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Treatment

• Medication
• Stem Cell Therapy
• Others

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Type

• Sporadic ALS
• Familial ALS

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market.

Available Customizations:

Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Medication [Riluzole, Edaravone, Others], Stem Cell Therapy, Others)
  • 5.2.2. By Type (Sporadic ALS, Familial ALS)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Distribution Channel

10. South America Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biogen
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Mitsubishi Tanabe Pharma
• 15.3. Sanofi
• 15.4. Roche
• 15.5. Amylyx Pharmaceuticals
• 15.6. Ionis Pharmaceuticals
• 15.7. Wave Life Sciences
• 15.8. Orphazyme
• 15.9. Cleveland Clinic Spinouts
• 15.10. Lundbeck

16. Strategic Recommendations

17. About Us & Disclaimer